Complement and its role in protection and pathogenesis of flavivirus infections

Vaccine

Volumn 26, Issue SUPPL. 8, 2008, Pages

  Avirutnan, Panisadee ^a,b   Mehlhop, Erin ^a   Diamond, Michael S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Virus, Innate Immunity, Dengue, West Nile, Immune Evasion

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4B; COMPLEMENT MEMBRANE ATTACK COMPLEX;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT EVASION; COMPLEMENT FIXATION; COMPLEMENT SYSTEM; DENGUE VIRUS; FLAVIVIRUS; IMMUNOSURVEILLANCE; INNATE IMMUNITY; MACROPHAGE; NONHUMAN; OPSONIZATION; PRIORITY JOURNAL; VIRUS PATHOGENESIS; WEST NILE FLAVIVIRUS;

COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; FLAVIVIRUS INFECTIONS; HUMANS; IMMUNITY, INNATE;

EID: 57649165055     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.11.061     Document Type: Article

References (223)

1. Walport M.J. Complement. First of two parts. N Engl J Med 344 14 (2001) 1058-1066
2. Walport M.J. Complement. Second of two parts. N Engl J Med 344 15 (2001) 1140-1144
3. Manderson A.P., Pickering M.C., Botto M., Walport M.J., and Parish C.R. Continual low-level activation of the classical complement pathway. J Exp Med 194 6 (2001) 747-756
4. Bossi F., Fischetti F., Pellis V., Bulla R., Ferrero E., Mollnes T.E., et al. Platelet-activating factor and kinin-dependent vascular leakage as a novel functional activity of the soluble terminal complement complex. J Immunol 173 11 (2004) 6921-6927
5. Casarsa C., De Luigi A., Pausa M., De Simoni M.G., and Tedesco F. Intracerebroventricular injection of the terminal complement complex causes inflammatory reaction in the rat brain. Eur J Immunol 33 5 (2003) 1260-1270
6. Dobrina A., Pausa M., Fischetti F., Bulla R., Vecile E., Ferrero E., et al. Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivo. Blood 99 1 (2002) 185-192
7. Ishikawa S., Tsukada H., and Bhattacharya J. Soluble complex of complement increases hydraulic conductivity in single microvessels of rat lung. J Clin Invest 91 1 (1993) 103-109
8. Saadi S., and Platt J.L. Transient perturbation of endothelial integrity induced by natural antibodies and complement. J Exp Med 181 1 (1995) 21-31
9. Tedesco F., Pausa M., Nardon E., Introna M., Mantovani A., and Dobrina A. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med 185 9 (1997) 1619-1627
10. Morgan B.P. Regulation of the complement membrane attack pathway. Crit Rev Immunol 19 3 (1999) 173-198
11. Hawlisch H., Wills-Karp M., Karp C.L., and Kohl J. The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma. Mol Immunol 41 2-3 (2004) 123-131
12. Carroll M.C. The complement system in regulation of adaptive immunity. Nat Immunol 5 10 (2004) 981-986
13. Helmy K.Y., Katschke Jr. K.J., Gorgani N.N., Kljavin N.M., Elliott J.M., Diehl L., et al. CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell 124 5 (2006) 915-927
14. Hourcade D., Holers V.M., and Atkinson J.P. The regulators of complement activation (RCA) gene cluster. Adv Immunol 45 (1989) 381-416
15. Fukui A., Yuasa-Nakagawa T., Murakami Y., Funami K., Kishi N., Matsuda T., et al. Mapping of the sites responsible for factor I-cofactor activity for cleavage of C3b and C4b on human C4b-binding protein (C4bp) by deletion mutagenesis. J Biochem 132 5 (2002) 719-728
16. Krych-Goldberg M., and Atkinson J.P. Structure-function relationships of complement receptor type 1. Immunol Rev 180 (2001) 112-122
17. Liszewski M.K., Leung M., Cui W., Subramanian V.B., Parkinson J., Barlow P.N., et al. Dissecting sites important for complement regulatory activity in membrane cofactor protein (MCP; CD46). J Biol Chem 275 48 (2000) 37692-37701
18. Seya T., and Atkinson J.P. Functional properties of membrane cofactor protein of complement. Biochem J 264 2 (1989) 581-588
19. Kazatchkine M.D., Fearon D.T., and Austen K.F. Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol 122 1 (1979) 75-81
20. Krych M., Hauhart R., and Atkinson J.P. Structure-function analysis of the active sites of complement receptor type 1. J Biol Chem 273 15 (1998) 8623-8629
21. Krych-Goldberg M., Hauhart R.E., Subramanian V.B., Yurcisin II B.M., Crimmins D.L., Hourcade D.E., et al. Decay accelerating activity of complement receptor type 1 (CD35). Two active sites are required for dissociating C5 convertases. J Biol Chem 274 44 (1999) 31160-31168
22. Scharfstein J., Ferreira A., Gigli I., and Nussenzweig V. Human C4-binding protein. I. Isolation and characterization. J Exp Med 148 1 (1978) 207-222
23. Weiler J.M., Daha M.R., Austen K.F., and Fearon D.T. Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci USA 73 9 (1976) 3268-3272
24. Davies A., and Lachmann P.J. Membrane defence against complement lysis: the structure and biological properties of CD59. Immunol Res 12 3 (1993) 258-275
25. Meri S., Morgan B.P., Davies A., Daniels R.H., Olavesen M.G., Waldmann H., et al. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71 1 (1990) 1-9
26. Choi N.H., Nakano Y., Tobe T., Mazda T., and Tomita M. Incorporation of SP-40,40 into the soluble membrane attack complex (SMAC, SC5b-9) of complement. Int Immunol 2 5 (1990) 413-417
27. Jenne D.E., and Tschopp J. Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constituent of rat testis fluid. Proc Natl Acad Sci USA 86 18 (1989) 7123-7127
28. Kirszbaum L., Sharpe J.A., Murphy B., d'Apice A.J., Classon B., Hudson P., et al. Molecular cloning and characterization of the novel, human complement-associated protein, SP-40,40: a link between the complement and reproductive systems. EMBO J 8 3 (1989) 711-718
29. McDonald J.F., and Nelsestuen G.L. Potent inhibition of terminal complement assembly by clusterin: characterization of its impact on C9 polymerization. Biochemistry 36 24 (1997) 7464-7473
30. Tschopp J., Chonn A., Hertig S., and French L.E. Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9. J Immunol 151 4 (1993) 2159-2165
31. Bhakdi S., Kaflein R., Halstensen T.S., Hugo F., Preissner K.T., and Mollnes T.E. Complement S-protein (vitronectin) is associated with cytolytic membrane-bound C5b-9 complexes. Clin Exp Immunol 74 3 (1988) 459-464
32. Milis L., Morris C.A., Sheehan M.C., Charlesworth J.A., and Pussell B.A. Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9. Clin Exp Immunol 92 1 (1993) 114-119
33. Bos I.G., Hack C.E., and Abrahams J.P. Structural and functional aspects of C1-inhibitor. Immunobiology 205 4-5 (2002) 518-533
34. Carroll M.C. The role of complement and complement receptors in induction and regulation of immunity. Annu Rev Immunol 16 (1998) 545-568
35. Fearon D.T., and Carroll M.C. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu Rev Immunol 18 (2000) 393-422
36. Weis J.J., Tedder T.F., and Fearon D.T. Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes. Proc Natl Acad Sci USA 81 3 (1984) 881-885
37. Matsumoto A.K., Kopicky-Burd J., Carter R.H., Tuveson D.A., Tedder T.F., and Fearon D.T. Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19. J Exp Med 173 1 (1991) 55-64
38. Dempsey P.W., Allison M.E., Akkaraju S., Goodnow C.C., and Fearon D.T. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271 5247 (1996) 348-350
39. Green T.D., Montefiori D.C., and Ross T.M. Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. J Virol 77 3 (2003) 2046-2055
40. Ross T.M., Xu Y., Bright R.A., and Robinson H.L. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat Immunol 1 2 (2000) 127-131
41. Wang L., Sunyer J.O., and Bello L.J. Fusion to C3d enhances the immunogenicity of the E2 glycoprotein of type 2 bovine viral diarrhea virus. J Virol 78 4 (2004) 1616-1622
42. Ahearn J.M., Fischer M.B., Croix D., Goerg S., Ma M., Xia J., et al. Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen. Immunity 4 3 (1996) 251-262
43. Croix D.A., Ahearn J.M., Rosengard A.M., Han S., Kelsoe G., Ma M., et al. Antibody response to a T-dependent antigen requires B cell expression of complement receptors. J Exp Med 183 4 (1996) 1857-1864
44. Fischer M.B., Ma M., Goerg S., Zhou X., Xia J., Finco O., et al. Regulation of the B cell response to T-dependent antigens by classical pathway complement. J Immunol 157 2 (1996) 549-556
45. Molina H., Holers V.M., Li B., Fung Y., Mariathasan S., Goellner J., et al. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc Natl Acad Sci USA 93 8 (1996) 3357-3361
46. Barrington R.A., Pozdnyakova O., Zafari M.R., Benjamin C.D., and Carroll M.C. B lymphocyte memory: role of stromal cell complement and FcgammaRIIB receptors. J Exp Med 196 9 (2002) 1189-1199
47. Fischer M.B., Goerg S., Shen L., Prodeus A.P., Goodnow C.C., Kelsoe G., et al. Dependence of germinal center B cells on expression of CD21/CD35 for survival. Science 280 5363 (1998) 582-585
48. Wu X., Jiang N., Fang Y.F., Xu C., Mao D., Singh J., et al. Impaired affinity maturation in Cr2-/- mice is rescued by adjuvants without improvement in germinal center development. J Immunol 165 6 (2000) 3119-3127
49. Fearon D.T. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med 152 1 (1980) 20-30
50. Ghiran I., Barbashov S.F., Klickstein L.B., Tas S.W., Jensenius J.C., and Nicholson-Weller A. Complement receptor 1/CD35 is a receptor for mannan-binding lectin. J Exp Med 192 12 (2000) 1797-1808
51. Klickstein L.B., Barbashov S.F., Liu T., Jack R.M., and Nicholson-Weller A. Complement receptor type 1 (CR1 CD35) is a receptor for C1q. Immunity 7 3 (1997) 345-355
52. Tedder T.F., Fearon D.T., Gartland G.L., and Cooper M.D. Expression of C3b receptors on human be cells and myelomonocytic cells but not natural killer cells. J Immunol 130 4 (1983) 1668-1673
53. Bogers W.M., Stad R.K., Van Es L.A., and Daha M.R. Both Kupffer cells and liver endothelial cells play an important role in the clearance of IgA and IgG immune complexes. Res Immunol 143 2 (1992) 219-224
54. Craig M.L., Bankovich A.J., McElhenny J.L., and Taylor R.P. Clearance of anti-double-stranded DNA antibodies: the natural immune complex clearance mechanism. Arthritis Rheum 43 10 (2000) 2265-2275
55. Kinoshita T., Takeda J., Hong K., Kozono H., Sakai H., and Inoue K. Monoclonal antibodies to mouse complement receptor type 1 (CR1). Their use in a distribution study showing that mouse erythrocytes and platelets are CR1-negative. J Immunol 140 9 (1988) 3066-3072
56. Kurtz C.B., O'Toole E., Christensen S.M., and Weis J.H. The murine complement receptor gene family. IV. Alternative splicing of Cr2 gene transcripts predicts two distinct gene products that share homologous domains with both human CR2 and CR1. J Immunol 144 9 (1990) 3581-3591
57. Molina H., Kinoshita T., Inoue K., Carel J.C., and Holers V.M. A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2. J Immunol 145 9 (1990) 2974-2983
58. Chen Z., Koralov S.B., Gendelman M., Carroll M.C., and Kelsoe G. Humoral immune responses in Cr2-/- mice: enhanced affinity maturation but impaired antibody persistence. J Immunol 164 9 (2000) 4522-4532
59. Kopf M., Abel B., Gallimore A., Carroll M., and Bachmann M.F. Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat Med 8 4 (2002) 373-378
60. Suresh M., Molina H., Salvato M.S., Mastellos D., Lambris J.D., and Sandor M. Complement component 3 is required for optimal expansion of CD8 T cells during a systemic viral infection. J Immunol 170 2 (2003) 788-794
61. Fang Y., Xu C., Fu Y.X., Holers V.M., and Molina H. Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J Immunol 160 11 (1998) 5273-5279
62. Qin D., Wu J., Carroll M.C., Burton G.F., Szakal A.K., and Tew J.G. Evidence for an important interaction between a complement-derived CD21 ligand on follicular dendritic cells and CD21 on B cells in the initiation of IgG responses. J Immunol 161 9 (1998) 4549-4554
63. Pratt J.R., Basheer S.A., and Sacks S.H. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 8 6 (2002) 582-587
64. Stager S., Alexander J., Kirby A.C., Botto M., Rooijen N.V., Smith D.F., et al. Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses. Nat Med 9 10 (2003) 1287-1292
65. Rey-Millet C.A., Villiers C.L., Gabert F.M., Chesne S., and Colomb M.G. C3b covalently associated to tetanus toxin modulates TT processing and presentation by U937 cells. Mol Immunol 31 17 (1994) 1321-1327
66. Villiers M.B., Villiers C.L., Jacquier-Sarlin M.R., Gabert F.M., Journet A.M., and Colomb M.G. Covalent binding of C3b to tetanus toxin: influence on uptake/internalization of antigen by antigen-specific and non-specific B cells. Immunology 89 3 (1996) 348-355
67. Arvieux J., Yssel H., and Colomb M.G. Antigen-bound C3b and C4b enhance antigen-presenting cell function in activation of human T-cell clones. Immunology 65 2 (1988) 229-235
68. Jacquier-Sarlin M.R., Gabert F.M., Villiers M.B., and Colomb M.G. Modulation of antigen processing and presentation by covalently linked complement C3b fragment. Immunology 84 1 (1995) 164-170
69. Perrin-Cocon L.A., Villiers C.L., Salamero J., Gabert F., and Marche P.N. B cell receptors and complement receptors target the antigen to distinct intracellular compartments. J Immunol 172 6 (2004) 3564-3572
70. Serra V.A., Cretin F., Pepin E., Gabert F.M., and Marche P.N. Complement C3b fragment covalently linked to tetanus toxin increases lysosomal sodium dodecyl sulfate-stable HLA-DR dimer production. Eur J Immunol 27 10 (1997) 2673-2679
71. Cretin F.C., Serra V.A., Villiers M.B., Laharie A.M., Marche P.N., and Gabert F.M. C3b complexation diversifies naturally processed T cell epitopes. Mol Immunol 44 11 (2007) 2893-2899
72. Castellano G., Woltman A.M., Nauta A.J., Roos A., Trouw L.A., Seelen M.A., et al. Maturation of dendritic cells abrogates C1q production in vivo and in vitro. Blood 103 10 (2004) 3813-3820
73. Csomor E., Bajtay Z., Sandor N., Kristof K., Arlaud G.J., Thiel S., et al. Complement protein C1q induces maturation of human dendritic cells. Mol Immunol 44 13 (2007) 3389-3397
74. Castellano G., Woltman A.M., Schlagwein N., Xu W., Schena F.P., Daha M.R., et al. Immune modulation of human dendritic cells by complement. Eur J Immunol 37 10 (2007) 2803-2811
75. Cutler A.J., Botto M., van Essen D., Rivi R., Davies K.A., Gray D., et al. T cell-dependent immune response in C1q-deficient mice: defective interferon gamma production by antigen-specific T cells. J Exp Med 187 11 (1998) 1789-1797
76. Nash J.T., Taylor P.R., Botto M., Norsworthy P.J., Davies K.A., and Walport M.J. Immune complex processing in C1q-deficient mice. Clin Exp Immunol 123 2 (2001) 196-202
77. van Montfoort N., de Jong J.M., Schuurhuis D.H., van der Voort E.I., Camps M.G., Huizinga T.W., et al. A novel role of complement factor C1q in augmenting the presentation of antigen captured in immune complexes to CD8+ T lymphocytes. J Immunol 178 12 (2007) 7581-7586
78. Heath W.R., Belz G.T., Behrens G.M., Smith C.M., Forehan S.P., Parish I.A., et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 199 (2004) 9-26
79. Schuurhuis D.H., Ioan-Facsinay A., Nagelkerken B., van Schip J.J., Sedlik C., Melief C.J., et al. Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol 168 5 (2002) 2240-2246
80. Schuurhuis D.H., van Montfoort N., Ioan-Facsinay A., Jiawan R., Camps M., Nouta J., et al. Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J Immunol 176 8 (2006) 4573-4580
81. Mehlhop E., and Diamond M.S. Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J Exp Med 203 5 (2006) 1371-1381
82. Taylor P.R., Seixas E., Walport M.J., Langhorne J., and Botto M. Complement contributes to protective immunity against reinfection by Plasmodium chabaudi chabaudi parasites. Infect Immun 69 6 (2001) 3853-3859
83. Banki Z., Stoiber H., and Dierich M.P. HIV and human complement: inefficient virolysis and effective adherence. Immunol Lett 97 2 (2005) 209-214
84. Bernet J., Mullick J., Singh A.K., and Sahu A. Viral mimicry of the complement system. J Biosci 28 3 (2003) 249-264
85. Cummings K.L., Waggoner S.N., Tacke R., and Hahn Y.S. Role of complement in immune regulation and its exploitation by virus. Viral Immunol 20 4 (2007) 505-524
86. Favoreel H.W., Van de Walle G.R., Nauwynck H.J., and Pensaert M.B. Virus complement evasion strategies. J Gen Virol 84 Pt 1 (2003) 1-15
87. Lambris J.D., Ricklin D., and Geisbrecht B.V. Complement evasion by human pathogens. Nat Rev Microbiol 6 2 (2008) 132-142
88. Bajtay Z., Speth C., Erdei A., and Dierich M.P. Cutting edge: productive HIV-1 infection of dendritic cells via complement receptor type 3 (CR3, CD11b/CD18). J Immunol 173 8 (2004) 4775-4778
89. Banki Z., Kacani L., Rusert P., Pruenster M., Wilflingseder D., Falkensammer B., et al. Complement dependent trapping of infectious HIV in human lymphoid tissues. AIDS 19 5 (2005) 481-486
90. Bergelson J.M., Chan M., Solomon K.R., St John N.F., Lin H., and Finberg R.W. Decay-accelerating factor (CD55), a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses. Proc Natl Acad Sci USA 91 13 (1994) 6245-6248
91. Bouhlal H., Chomont N., Haeffner-Cavaillon N., Kazatchkine M.D., Belec L., and Hocini H. Opsonization of HIV-1 by semen complement enhances infection of human epithelial cells. J Immunol 169 6 (2002) 3301-3306
92. Cardosa M.J., Gordon S., Hirsch S., Springer T.A., and Porterfield J.S. Interaction of West Nile virus with primary murine macrophages: role of cell activation and receptors for antibody and complement. J Virol 57 3 (1986) 952-959
93. Cardosa M.J., Porterfield J.S., and Gordon S. Complement receptor mediates enhanced flavivirus replication in macrophages. J Exp Med 158 1 (1983) 258-263
94. Chen M., Sallberg M., Hughes J., Jones J., Guidotti L.G., Chisari F.V., et al. Immune tolerance split between hepatitis B virus precore and core proteins. J Virol 79 5 (2005) 3016-3027
95. Chen M.T., Billaud J.N., Sallberg M., Guidotti L.G., Chisari F.V., Jones J., et al. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc Natl Acad Sci USA 101 41 (2004) 14913-14918
96. Coyne C.B., and Bergelson J.M. Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell 124 1 (2006) 119-131
97. Delibrias C.C., Mouhoub A., Fischer E., and Kazatchkine M.D. CR1(CD35) and CR2(CD21) complement C3 receptors are expressed on normal human thymocytes and mediate infection of thymocytes with opsonized human immunodeficiency virus. Eur J Immunol 24 11 (1994) 2784-2788
98. Doepper S., Stoiber H., Kacani L., Sprinzl G., Steindl F., Prodinger W.M., et al. B cell-mediated infection of stimulated and unstimulated autologous T lymphocytes with HIV-1: role of complement. Immunobiology 202 3 (2000) 293-305
99. Dopper S., Wilflingseder D., Prodinger W.M., Stiegler G., Speth C., Dierich M.P., et al. Mechanism(s) promoting HIV-1 infection of primary unstimulated T lymphocytes in autologous B cell/T cell co-cultures. Eur J Immunol 33 8 (2003) 2098-2107
100. Dorig R.E., Marcil A., Chopra A., and Richardson C.D. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75 2 (1993) 295-305
101. Eisen-Vandervelde A.L., Waggoner S.N., Yao Z.Q., Cale E.M., Hahn C.S., and Hahn Y.S. Hepatitis C virus core selectively suppresses interleukin-12 synthesis in human macrophages by interfering with AP-1 activation. J Biol Chem 279 42 (2004) 43479-43486
102. Fingeroth J.D., Weis J.J., Tedder T.F., Strominger J.L., Biro P.A., and Fearon D.T. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci USA 81 14 (1984) 4510-4514
103. Gaggar A., Shayakhmetov D.M., and Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med 9 11 (2003) 1408-1412
104. Jakubik J.J., Saifuddin M., Takefman D.M., and Spear G.T. B lymphocytes in lymph nodes and peripheral blood are important for binding immune complexes containing HIV-1. Immunology 96 4 (1999) 612-619
105. Kacani L., Prodinger W.M., Sprinzl G.M., Schwendinger M.G., Spruth M., Stoiber H., et al. Detachment of human immunodeficiency virus type 1 from germinal centers by blocking complement receptor type 2. J Virol 74 17 (2000) 7997-8002
106. Kacani L., Banki Z., Zwirner J., Schennach H., Bajtay Z., Erdei A., et al. C5a and C5a(desArg) enhance the susceptibility of monocyte-derived macrophages to HIV infection. J Immunol 166 5 (2001) 3410-3415
107. Karp C.L., Wysocka M., Wahl L.M., Ahearn J.M., Cuomo P.J., Sherry B., et al. Mechanism of suppression of cell-mediated immunity by measles virus. Science 273 5272 (1996) 228-231
108. Kittlesen D.J., Chianese-Bullock K.A., Yao Z.Q., Braciale T.J., and Hahn Y.S. Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. J Clin Invest 106 10 (2000) 1239-1249
109. Kurita-Taniguchi M., Fukui A., Hazeki K., Hirano A., Tsuji S., Matsumoto M., et al. Functional modulation of human macrophages through CD46 (measles virus receptor): production of IL-12 p40 and nitric oxide in association with recruitment of protein-tyrosine phosphatase SHP-1 to CD46. J Immunol 165 9 (2000) 5143-5152
110. Laine S., Thouard A., Derancourt J., Kress M., Sitterlin D., and Rossignol J.M. In vitro and in vivo interactions between the hepatitis B virus protein P22 and the cellular protein gC1qR. J Virol 77 23 (2003) 12875-12880
111. Lee C.H., Choi Y.H., Yang S.H., Lee C.W., Ha S.J., and Sung Y.C. Hepatitis C virus core protein inhibits interleukin 12 and nitric oxide production from activated macrophages. Virology 279 1 (2001) 271-279
112. Liang X., Shin Y.C., Means R.E., and Jung J.U. Inhibition of interferon-mediated antiviral activity by murine gammaherpesvirus 68 latency-associated M2 protein. J Virol 78 22 (2004) 12416-12427
113. Marttila M., Persson D., Gustafsson D., Liszewski M.K., Atkinson J.P., Wadell G., et al. CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7. J Virol 79 22 (2005) 14429-14436
114. Montefiori D.C., Graham B.S., Zhou J.Y., Zhou J.T., and Ahearn J.M. Binding of human immunodeficiency virus type 1 to the C3b/C4b receptor CR1 (CD35) and red blood cells in the presence of envelope-specific antibodies and complement. National Institutes of Health AIDS Vaccine Clinical Trials Networks. J Infect Dis 170 2 (1994) 429-432
115. Mouhoub A., Delibrias C.C., Fischer E., Boyer V., and Kazatchkine M.D. Ligation of CR1 (C3b receptor, CD35) on CD4+ T lymphocytes enhances viral replication in HIV-infected cells. Clin Exp Immunol 106 2 (1996) 297-303
116. Nemerow G.R., Mold C., Schwend V.K., Tollefson V., and Cooper N.R. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J Virol 61 5 (1987) 1416-1420
117. Nielsen S.D., Sorensen A.M., Schonning K., Lund O., Nielsen J.O., and Hansen J.E. Complement-mediated enhancement of HIV-1 infection in peripheral blood mononuclear cells. Scand J Infect Dis 29 5 (1997) 447-452
118. Salhi S., Messageot F., Carlier D., Jean-Jean O., and Rossignol J.M. Identification of a cellular protein specifically interacting with the precursor of the hepatitis B e antigen. J Viral Hepat 8 3 (2001) 169-173
119. Santoro F., Kennedy P.E., Locatelli G., Malnati M.S., Berger E.A., and Lusso P. CD46 is a cellular receptor for human herpesvirus 6. Cell 99 7 (1999) 817-827
120. Segerman A., Atkinson J.P., Marttila M., Dennerquist V., Wadell G., and Arnberg N. Adenovirus type 11 uses CD46 as a cellular receptor. J Virol 77 17 (2003) 9183-9191
121. Smith A., Santoro F., Di Lullo G., Dagna L., Verani A., and Lusso P. Selective suppression of IL-12 production by human herpesvirus 6. Blood 102 8 (2003) 2877-2884
122. Tacnet-Delorme P., Boyer V., Thielens N.M., Hernandez J.F., Bally I., Sim R.B., et al. In vitro analysis of complement-dependent HIV-1 cell infection using a model system. J Immunol 162 7 (1999) 4088-4093
123. Tanner J., Weis J., Fearon D., Whang Y., and Kieff E. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell 50 2 (1987) 203-213
124. Thieblemont N., Haeffner-Cavaillon N., Ledur A., L'Age-Stehr J., Ziegler-Heitbrock H.W., and Kazatchkine M.D. CR1 (CD35) and CR3 (CD11b/CD18) mediate infection of human monocytes and monocytic cell lines with complement-opsonized HIV independently of CD4. Clin Exp Immunol 92 1 (1993) 106-113
125. Thieblemont N., Haeffner-Cavaillon N., Haeffner A., Cholley B., Weiss L., and Kazatchkine M.D. Triggering of complement receptors CR1 (CD35) and CR3 (CD11b/CD18) induces nuclear translocation of NF-kappa B (p50/p65) in human monocytes and enhances viral replication in HIV-infected monocytic cells. J Immunol 155 10 (1995) 4861-4867
126. Waggoner S.N., Hall C.H., and Hahn Y.S. HCV core protein interaction with gC1q receptor inhibits Th1 differentiation of CD4+ T cells via suppression of dendritic cell IL-12 production. J Leukoc Biol 82 6 (2007) 1407-1419
127. Bonaparte R.S., Hair P.S., Banthia D., Marshall D.M., Cunnion K.M., and Krishna N.K. Human astrovirus coat protein inhibits serum complement activation via C1, the first component of the classical pathway. J Virol 82 2 (2008) 817-827
128. Favoreel H.W., Nauwynck H.J., Van Oostveldt P., Mettenleiter T.C., and Pensaert M.B. Antibody-induced and cytoskeleton-mediated redistribution and shedding of viral glycoproteins, expressed on pseudorabies virus-infected cells. J Virol 71 11 (1997) 8254-8261
129. Johnson D.C., and Feenstra V. Identification of a novel herpes simplex virus type 1-induced glycoprotein which complexes with gE and binds immunoglobulin. J Virol 61 7 (1987) 2208-2216
130. Johnson D.C., Frame M.C., Ligas M.W., Cross A.M., and Stow N.D. Herpes simplex virus immunoglobulin G Fc receptor activity depends on a complex of two viral glycoproteins, gE and gI. J Virol 62 4 (1988) 1347-1354
131. Kostavasili I., Sahu A., Friedman H.M., Eisenberg R.J., Cohen G.H., and Lambris J.D. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus. J Immunol 158 4 (1997) 1763-1771
132. Litwin V., and Grose C. Herpesviral Fc receptors and their relationship to the human Fc receptors. Immunol Res 11 3-4 (1992) 226-238
133. Lubinski J.M., Jiang M., Hook L., Chang Y., Sarver C., Mastellos D., et al. Herpes simplex virus type 1 evades the effects of antibody and complement in vivo. J Virol 76 18 (2002) 9232-9241
134. Nagashunmugam T., Lubinski J., Wang L., Goldstein L.T., Weeks B.S., Sundaresan P., et al. In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor. J Virol 72 7 (1998) 5351-5359
135. Oleszak E.L., Perlman S., Parr R., Collisson E.W., and Leibowitz J.L. Molecular mimicry between S peplomer proteins of coronaviruses (MHV, BCV, TGEV and IBV) and Fc receptor. Adv Exp Med Biol 342 (1993) 183-188
136. Thale R., Lucin P., Schneider K., Eggers M., and Koszinowski U.H. Identification and expression of a murine cytomegalovirus early gene coding for an Fc receptor. J Virol 68 12 (1994) 7757-7765
137. Nomura M., Kurita-Taniguchi M., Kondo K., Inoue N., Matsumoto M., Yamanishi K., et al. Mechanism of host cell protection from complement in murine cytomegalovirus (CMV) infection: identification of a CMV-responsive element in the CD46 promoter region. Eur J Immunol 32 10 (2002) 2954-2964
138. Spiller O.B., Morgan B.P., Tufaro F., and Devine D.V. Altered expression of host-encoded complement regulators on human cytomegalovirus-infected cells. Eur J Immunol 26 7 (1996) 1532-1538
139. Takemoto M., Yamanishi K., and Mori Y. Human herpesvirus 7 infection increases the expression levels of CD46 and CD59 in target cells. J Gen Virol 88 Pt 5 (2007) 1415-1422
140. Frank I., Stoiber H., Godar S., Stockinger H., Steindl F., Katinger H.W., et al. Acquisition of host cell-surface-derived molecules by HIV-1. AIDS 10 14 (1996) 1611-1620
141. Marschang P., Sodroski J., Wurzner R., and Dierich M.P. Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur J Immunol 25 1 (1995) 285-290
142. Schmitz J., Zimmer J.P., Kluxen B., Aries S., Bogel M., Gigli I., et al. Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59. J Clin Invest 96 3 (1995) 1520-1526
143. Takefman D.M., Sullivan B.L., Sha B.E., and Spear G.T. Mechanisms of resistance of HIV-1 primary isolates to complement-mediated lysis. Virology 246 2 (1998) 370-378
144. Vanderplasschen A., Mathew E., Hollinshead M., Sim R.B., and Smith G.L. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc Natl Acad Sci USA 95 13 (1998) 7544-7549
145. Saifuddin M., Hedayati T., Atkinson J.P., Holguin M.H., Parker C.J., and Spear G.T. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J Gen Virol 78 Pt 8 (1997) 1907-1911
146. Spear G.T., Lurain N.S., Parker C.J., Ghassemi M., Payne G.H., and Saifuddin M. Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). J Immunol 155 9 (1995) 4376-4381
147. Chung K.M., Liszewski M.K., Nybakken G., Davis A.E., Townsend R.R., Fremont D.H., et al. West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc Natl Acad Sci USA 103 50 (2006) 19111-19116
148. Pinter C., Siccardi A.G., Longhi R., and Clivio A. Direct interaction of complement factor H with the C1 domain of HIV type 1 glycoprotein 120. AIDS Res Hum Retroviruses 11 5 (1995) 577-588
149. Pinter C., Siccardi A.G., Lopalco L., Longhi R., and Clivio A. HIV glycoprotein 41 and complement factor H interact with each other and share functional as well as antigenic homology. AIDS Res Hum Retroviruses 11 8 (1995) 971-980
150. Stoiber H., Schneider R., Janatova J., and Dierich M.P. Human complement proteins C3b, C4b, factor H and properdin react with specific sites in gp120 and gp41, the envelope proteins of HIV-1. Immunobiology 193 1 (1995) 98-113
151. Stoiber H., Pinter C., Siccardi A.G., Clivio A., and Dierich M.P. Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J Exp Med 183 1 (1996) 307-310
152. Albrecht J.C., Nicholas J., Cameron K.R., Newman C., Fleckenstein B., and Honess R.W. Herpesvirus saimiri has a gene specifying a homologue of the cellular membrane glycoprotein CD59. Virology 190 1 (1992) 527-530
153. Fodor W.L., Rollins S.A., Bianco-Caron S., Rother R.P., Guilmette E.R., Burton W.V., et al. The complement control protein homolog of herpesvirus saimiri regulates serum complement by inhibiting C3 convertase activity. J Virol 69 6 (1995) 3889-3892
154. Liszewski M.K., Leung M.K., Hauhart R., Buller R.M., Bertram P., Wang X., et al. Structure and regulatory profile of the monkeypox inhibitor of complement: comparison to homologs in vaccinia and variola and evidence for dimer formation. J Immunol 176 6 (2006) 3725-3734
155. McKenzie R., Kotwal G.J., Moss B., Hammer C.H., and Frank M.M. Regulation of complement activity by vaccinia virus complement-control protein. J Infect Dis 166 6 (1992) 1245-1250
156. Miller C.G., Shchelkunov S.N., and Kotwal G.J. The cowpox virus-encoded homolog of the vaccinia virus complement control protein is an inflammation modulatory protein. Virology 229 1 (1997) 126-133
157. Rosengard A.M., Liu Y., Nie Z., and Jimenez R. Variola virus immune evasion design: expression of a highly efficient inhibitor of human complement. Proc Natl Acad Sci USA 99 13 (2002) 8808-8813
158. Singh A.K., Mullick J., Bernet J., and Sahu A. Functional characterization of the complement control protein homolog of herpesvirus saimiri: ARG-118 is critical for factor I cofactor activities. J Biol Chem 281 32 (2006) 23119-23128
159. Spiller O.B., Robinson M., O'Donnell E., Milligan S., Morgan B.P., Davison A.J., et al. Complement regulation by Kaposi's sarcoma-associated herpesvirus ORF4 protein. J Virol 77 1 (2003) 592-599
160. Blue C.E., Spiller O.B., and Blackbourn D.J. The relevance of complement to virus biology. Virology 319 2 (2004) 176-184
161. Hirsch R.L., Griffin D.E., and Winkelstein J.A. The effect of complement depletion on the course of Sindbis virus infection in mice. J Immunol 121 4 (1978) 1276-1278
162. Hirsch R.L., Griffin D.E., and Winkelstein J.A. Role of complement in viral infections: participation of terminal complement components (C5 to C9) in recovery of mice from Sindbis virus infection. Infect Immun 30 3 (1980) 899-901
163. Hirsch R.L., Griffin D.E., and Winkelstein J.A. The role of complement in viral infections. II. The clearance of Sindbis virus from the bloodstream and central nervous system of mice depleted of complement. J Infect Dis 141 2 (1980) 212-217
164. Jayasekera J.P., Moseman E.A., and Carroll M.C. Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. J Virol 81 7 (2007) 3487-3494
165. Mozdzanowska K., Feng J., Eid M., Zharikova D., and Gerhard W. Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components. Virology 352 2 (2006) 418-426
166. Spear G.T., Hart M., Olinger G.G., Hashemi F.B., and Saifuddin M. The role of the complement system in virus infections. Curr Top Microbiol Immunol 260 (2001) 229-245
167. Gubler D.J., Kuno G., and Markoff L. Flaviviruses. In: Knipe D.M., and Howley P.M. (Eds). Fields' virology. 5th ed. (2007), Lippincott Williams & Wilkins, a Wolters Kluwer Business, Philadelphia 1153-1252
168. Lindenbach B.D., Thiel H.-J., and Rice C. Flaviviridae: the viruses and their replication. In: Knipe D.M., and Howley P.M. (Eds). Fields' virology. 5th ed. (2007), Lippincott Williams & Wilkins, a Wolters Kluwer Business, Philadelphia 1101-1152
169. Winkler G., Maxwell S.E., Ruemmler C., and Stollar V. Newly synthesized dengue-2 virus nonstructural protein NS1 is a soluble protein but becomes partially hydrophobic and membrane-associated after dimerization. Virology 171 1 (1989) 302-305
170. Winkler G., Randolph V.B., Cleaves G.R., Ryan T.E., and Stollar V. Evidence that the mature form of the flavivirus nonstructural protein NS1 is a dimer. Virology 162 1 (1988) 187-196
171. Lindenbach B.D., and Rice C.M. Genetic interaction of flavivirus nonstructural proteins NS1 and NS4A as a determinant of replicase function. J Virol 73 6 (1999) 4611-4621
172. Mackenzie J.M., Jones M.K., and Young P.R. Immunolocalization of the dengue virus nonstructural glycoprotein NS1 suggests a role in viral RNA replication. Virology 220 1 (1996) 232-240
173. Flamand M., Megret F., Mathieu M., Lepault J., Rey F.A., and Deubel V. Dengue virus type 1 nonstructural glycoprotein NS1 is secreted from mammalian cells as a soluble hexamer in a glycosylation-dependent fashion. J Virol 73 7 (1999) 6104-6110
174. Avirutnan P., Punyadee N., Noisakran S., Komoltri C., Thiemmeca S., Auethavornanan K., et al. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J Infect Dis 193 8 (2006) 1078-1088
175. Avirutnan P., Zhang L., Punyadee N., Manuyakorn A., Puttikhunt C., Kasinrerk W., et al. Secreted NS1 of dengue virus attaches to the surface of cells via interactions with heparan sulfate and chondroitin sulfate E. PLoS Pathog 3 11 (2007) e183
176. Libraty D.H., Young P.R., Pickering D., Endy T.P., Kalayanarooj S., Green S., et al. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J Infect Dis 186 8 (2002) 1165-1168
177. Wilson J.R., de Sessions P.F., Leon M.A., and Scholle F. West Nile virus nonstructural protein 1 inhibits TLR3 signal transduction. J Virol 82 17 (2008) 8262-8271
178. Mehlhop E., Whitby K., Oliphant T., Marri A., Engle M., and Diamond M.S. Complement activation is required for induction of a protective antibody response against West Nile virus infection. J Virol 79 12 (2005) 7466-7477
179. Pathogenetic mechanisms in dengue haemorrhagic fever: report of an international collaborative study. Bull World Health Organ 48 1 (1973) 117-133
180. Bokisch V.A., Top Jr. F.H., Russell P.K., Dixon F.J., and Muller-Eberhard H.J. The potential pathogenic role of complement in dengue hemorrhagic shock syndrome. N Engl J Med 289 19 (1973) 996-1000
181. Malasit P. Complement and dengue haemorrhagic fever/shock syndrome. Southeast Asian J Trop Med Public Health 18 3 (1987) 316-320
182. Beebe D.P., Schreiber R.D., and Cooper N.R. Neutralization of influenza virus by normal human sera: mechanisms involving antibody and complement. J Immunol 130 3 (1983) 1317-1322
183. Aasa-Chapman M.M., Holuigue S., Aubin K., Wong M., Jones N.A., Cornforth D., et al. Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. J Virol 79 5 (2005) 2823-2830
184. Posner M.R., Elboim H.S., Cannon T., Cavacini L., and Hideshima T. Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis. AIDS Res Hum Retroviruses 8 5 (1992) 553-558
185. Spear G.T., Takefman D.M., Sullivan B.L., Landay A.L., and Zolla-Pazner S. Complement activation by human monoclonal antibodies to human immunodeficiency virus. J Virol 67 1 (1993) 53-59
186. Verity E.E., Williams L.A., Haddad D.N., Choy V., O'Loughlin C., Chatfield C., et al. Broad neutralization and complement-mediated lysis of HIV-1 by PEHRG214, a novel caprine anti-HIV-1 polyclonal antibody. AIDS 20 4 (2006) 505-515
187. Baughman R.H., Fenters J.D., Marquis Jr. G.S., and Holper J.C. Effect of complement and viral filtration on the neutralization of respiratory syncytial virus. Appl Microbiol 16 7 (1968) 1076-1080
188. Yoder S.M., Zhu Y., Ikizler M.R., and Wright P.F. Role of complement in neutralization of respiratory syncytial virus. J Med Virol 72 4 (2004) 688-694
189. Beebe D.P., and Cooper N.R. Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum. J Immunol 126 4 (1981) 1562-1568
190. Grose C., Edmond B.J., and Brunell P.A. Complement-enhanced neutralizing antibody response to varicella-zoster virus. J Infect Dis 139 4 (1979) 432-437
191. Schmidt N.J., and Lennette E.H. Neutralizing antibody responses to varicella-zoster virus. Infect Immun 12 3 (1975) 606-613
192. Nemerow G.R., Jensen F.C., and Cooper N.R. Neutralization of Epstein-Barr virus by nonimmune human serum. Role of cross-reacting antibody to herpes simplex virus and complement. J Clin Invest 70 5 (1982) 1081-1091
193. Sairenji T., Sullivan J.L., and Humphreys R.E. Complement-dependent, Epstein-Barr virus-neutralizing antibody appearing early in the sera of patients with infectious mononucleosis. J Infect Dis 149 5 (1984) 763-768
194. Lerner A.M., Shippey M.J., and Crane L.R. Serologic responses to herpes simplex virus in rabbits: complement-requiring neutralizing, conventional neutralizing, and passive hemagglutinating antibodies. J Infect Dis 129 6 (1974) 623-636
195. Snyder D.B., Myrup A.C., and Dutta S.K. Complement requirement for virus neutralization by antibody and reduced serum complement levels associated with experimental equine herpesvirus 1 infection. Infect Immun 31 2 (1981) 636-640
196. Wallis C., and Melnick J.L. Herpesvirus neutralization: the role of complement. J Immunol 107 5 (1971) 1235-1242
197. Della-Porta A.J., and Westaway E.G. Immune response in rabbits to virion and nonvirion antigens of the Flavivirus kunjin. Infect Immun 15 3 (1977) 874-882
198. Sabin A.B. The dengue group of viruses and its family relationships. Bacteriol Rev 14 3 (1950) 225-232
199. Spector S.L., and Tauraso N.M. Yellow fever virus. II. Factors affecting the plaque neutralization test. Appl Microbiol 18 5 (1969) 736-743
200. Schlesinger J.J., and Chapman S. Neutralizing F(ab′)2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis. J Gen Virol 76 Pt 1 (1995) 217-220
201. Gollins S.W., and Porterfield J.S. Flavivirus infection enhancement in macrophages: radioactive and biological studies on the effect of antibody on viral fate. J Gen Virol 65 Pt 8 (1984) 1261-1272
202. Gollins S.W., and Porterfield J.S. Flavivirus infection enhancement in macrophages: an electron microscopic study of viral cellular entry. J Gen Virol 66 Pt 9 (1985) 1969-1982
203. Halstead S.B., and O'Rourke E.J. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 146 1 (1977) 201-217
204. Kliks S.C., Nisalak A., Brandt W.E., Wahl L., and Burke D.S. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 40 4 (1989) 444-451
205. Peiris J.S., Gordon S., Unkeless J.C., and Porterfield J.S. Monoclonal anti-Fc receptor IgG blocks antibody enhancement of viral replication in macrophages. Nature 289 5794 (1981) 189-191
206. Peiris J.S., and Porterfield J.S. Antibody-mediated enhancement of Flavivirus replication in macrophage-like cell lines. Nature 282 5738 (1979) 509-511
207. Halstead S.B. Pathogenesis of dengue: challenges to molecular biology. Science 239 4839 (1988) 476-481
208. Mehlhop E., Ansarah-Sobrinho C., Johnson S., Engle M., Fremont D.H., Pierson T.C., et al. Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe 2 6 (2007) 417-426
209. Yamanaka A., Kosugi S., and Konishi E. Infection-enhancing and -neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels. J Virol 82 2 (2008) 927-937
210. Bindon C.I., Hale G., Bruggemann M., and Waldmann H. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med 168 1 (1988) 127-142
211. Cooper N.R. The classical complement pathway: activation and regulation of the first complement component. Adv Immunol 37 (1985) 151-216
212. Nimmannitya S. Clinical spectrum and management of dengue haemorrhagic fever. Southeast Asian J Trop Med Public Health 18 3 (1987) 392-397
213. Green S., and Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 19 5 (2006) 429-436
214. Kurane I. Dengue hemorrhagic fever with special emphasis on immunopathogenesis. Comp Immunol Microbiol Infect Dis 30 5-6 (2007) 329-340
215. Pang T., Cardosa M.J., and Guzman M.G. Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS). Immunol Cell Biol 85 1 (2007) 43-45
216. Churdboonchart V., Bhamarapravati N., and Futrakul P. Crossed immunoelectrophoresis for the detection of split products of the third complement in dengue hemorrhagic fever. I. Observations in patients' plasma. Am J Trop Med Hyg 32 3 (1983) 569-576
217. Theofilopoulos A.N., Wilson C.B., and Dixon F.J. The Raji cell radioimmune assay for detecting immune complexes in human sera. J Clin Invest 57 1 (1976) 169-182
218. Bhakdi S., and Kazatchkine M.D. Pathogenesis of dengue: an alternative hypothesis. Southeast Asian J Trop Med Public Health 21 4 (1990) 652-657
219. Avirutnan P., Malasit P., Seliger B., Bhakdi S., and Husmann M. Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis. J Immunol 161 11 (1998) 6338-6346
220. Zipfel P.F., Skerka C., Hellwage J., Jokiranta S.T., Meri S., Brade V., et al. Factor H family proteins: on complement, microbes and human diseases. Biochem Soc Trans 30 Pt 6 (2002) 971-978
221. Brandt W.E., Chiewslip D., Harris D.L., and Russell P.K. Partial purification and characterization of a dengue virus soluble complement-fixing antigen. J Immunol 105 6 (1970) 1565-1568
222. McCloud T.G., Brandt W.E., and Russell P.K. Molecular size and charge relationships of the soluble complement-fixing antigens of dengue viruses. Virology 41 3 (1970) 569-572
223. Kurosu T., Chaichana P., Yamate M., Anantapreecha S., and Ikuta K. Secreted complement regulatory protein clusterin interacts with dengue virus nonstructural protein 1. Biochem Biophys Res Commun 362 4 (2007) 1051-1056